Welcome to the Boehringer Ingelheim Pharmaceuticals Inc.(BIPI) and Lilly USA, LLC (Lilly) Alliance on-line application and grant management portal.

      On January 11, 2011 BIPI and Lilly announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and measurably improves health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.

      By agreement between BIPI and Lilly, grant requests will be processed through the BIPI on-line grant system but the application request will be reviewed by both companies. Please review the following prior to submitting a request through our on-line system.

      Medical Education Grants

      A BIPI/Lilly medical education grant is designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.

      Please see below for submission timelines:

      • Grant applications must be submitted no less than 60 days prior to the program start date.

      New and Returning Visitors to BIPI/Lilly Medical Grants

      To begin a new application, return to a saved application, or track the status of an application already submitted login at https://bipisupport.envisionpharma.com/vt_bi/. If this is the first time you are visiting the site, you must register as a New User. An application ID beginning with "ME", will be assigned once you submit the application.

      Educational Objectives - Diabetes

      • Support individualized treatment, including goal-setting (glycemic and others) based upon scientific evidence and the patients' underlying pathophysiology, and identify patient groups/characteristics most likely to benefit from particular therapies.
      • Improve awareness of the importance of early detection of renal dysfunction and appropriate glycemic management in patients with T2DM to reduce the risk of microvascular complications.
      • Enhance clinicians' knowledge of the role of incretin based therapies in practice recommendations for the treatment of patients with T2DM.
      • Strengthen clinicians' understanding of the role of therapeutic classes and agents with glucuretic mechanisms of action in practice recommendations for the treatment of patients with T2DM.
      • Enhance clinicians' knowledge in developing individualized approaches for effectively improving outcomes in relation to the macrovascular complications of diabetes such as myocardial infarction and stroke.
      • Foster an understanding of the scientific and clinical evidence supporting early and comprehensive interventions that address multiple pathophysiologic drivers of type 2 diabetes, and understand the possible impact of this approach on limiting disease progression.

      Responding to a Request for Educational Grant Application (REGA)
      Throughout the year, the Medical Grants department may announce a Request for Educational Grant Application (REGA). The intent of this announcement is to notify experienced and accredited Continuing Medical Education (CME) providers and accredited Continuing Education (CE) providers that BIPI/Lilly is interested in receiving applications for educational grants for support consideration.

      Grant applications in response to BIPI/Lilly Alliance REGAs need to be submitted online at https://bipisupport.envisionpharma.com/vt_bi. While REGAs may specify timing of requested responses, BIPI and Lilly will continue to review all grant requests which are received.

      To contact the BIPI/Lilly Alliance Medical Grants Department, please send an email to medgrnts.rdg@boehringer-ingelheim.com.